Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Obstetrics and gynaecology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Postpartum venous thromboembolism

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Do not normalise postpartum breathlessness

Sudden breathlessness, pleuritic pain, haemoptysis, syncope or collapse after birth may indicate pulmonary embolism, even in a woman already receiving prophylactic injections.

Action: Arrange emergency assessment and immediate resuscitation for instability. Obtain senior obstetric and medical input, begin appropriate anticoagulation unless contraindicated, and expedite objective testing without attributing symptoms to anxiety.

Overview

Recognise thromboembolism after birth, distinguish prevention from therapeutic anticoagulation, and coordinate investigation, breastfeeding-compatible treatment and a safe post-discharge medication plan.

The puerperium combines persisting prothrombotic changes with potential tissue injury and reduced mobility. A woman who was mobile and well at discharge can acquire additional risks through infection, wound pain, dehydration or readmission. Risk assessment is therefore a repeated clinical task rather than a completed box in the antenatal record. Ask about previous venous thromboembolism, thrombophilia, obesity, operative birth, major bleeding and current mobility, then use the approved maternity risk assessment to decide preventive treatment.

Prevention and treatment use different doses and answer different questions. Postpartum prophylaxis may be prescribed for ten days or six weeks according to risk, with extensions when important risk factors persist. A patient who develops possible DVT or PE while using a prophylactic dose still needs urgent investigation and consideration of therapeutic anticoagulation. Do not reassure her that injections make a clot impossible. Establish whether doses were actually taken, but avoid implying blame when symptoms occur despite adherence.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Treatment duration after a late diagnosis

A woman develops a confirmed proximal DVT five weeks after giving birth. She has no continuing risk factor beyond the recent pregnancy. Which minimum duration principle should guide the planned anticoagulation stop date?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status5 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • RCOG Green-top 37a postpartum thromboprophylaxis
  • RCOG Green-top 37b acute pregnancy and puerperal thrombosis
  • NHS SPS oral anticoagulants during breastfeeding
  • Inhixa enoxaparin summary of product characteristics
  • NICE NG194 postnatal care recommendations

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

DVT commonly produces unilateral swelling and discomfort, while pulmonary embolism may present with abrupt dyspnoea, chest pain, haemoptysis or collapse. Mild physiological postpartum symptoms overlap with these presentations, which makes focused assessment more useful than assumptions based on age. Whole-leg swelling with back or buttock pain raises the possibility of iliac thrombosis that a limited calf examination may miss. Symmetric ankle swelling is less specific, but it does not independently exclude thromboembolism elsewhere.

Objective investigation should follow the obstetric pathway promptly. Compression duplex ultrasound is used for suspected DVT. Suspected PE usually requires chest assessment and definitive imaging with CTPA or a ventilation–perfusion study, selected according to the clinical situation and local radiology advice. The RCOG pathway does not recommend using D-dimer as a stand-alone exclusion test in pregnancy-associated suspected VTE. Likewise, routine adult clinical scoring should not replace the maternity diagnostic pathway.

Therapeutic LMWH is often used initially while testing proceeds unless bleeding or another important contraindication requires a different senior plan. Recent postpartum haemorrhage, wound bleeding and neuraxial procedures make timing decisions more complex, but leaving a serious suspected embolism untreated also has consequences. Involve obstetrics, anaesthesia and haematology when these risks compete. Haemodynamically unstable PE needs an emergency multidisciplinary decision about reperfusion and critical care, not simply the next scheduled subcutaneous dose.

Longer-term treatment should fit the woman's clinical situation and daily life. Discuss self-injection, sharps disposal, monitoring, transport to blood tests, breastfeeding and how to obtain prescriptions. RCOG requires at least three months of anticoagulation in total and coverage for at least six weeks after birth, with ongoing risk reviewed before stopping. A DVT first diagnosed several weeks postpartum therefore needs substantially more treatment than merely finishing the sixth week.

Breastfeeding advice is medicine-specific and has evolved since the 2015 RCOG documents. Warfarin remains SPS's preferred oral option, with extensive experience; LMWH is also compatible. Current SPS guidance permits consideration of rivaroxaban or dabigatran when clinically indicated for a full-term healthy infant, while other DOACs have different recommendations and individual product labels may be more restrictive. A specialist should reconcile these sources and document the decision rather than assuming that every oral anticoagulant has the same lactation profile.

Key points

  • Postpartum thrombosis risk remains important after discharge from maternity care.
  • Reassess prevention needs after infection, haemorrhage, surgery or readmission.
  • Prophylactic low-molecular-weight heparin does not treat an established clot.
  • Investigate suspected thrombosis promptly with appropriate objective imaging.
  • Treatment must satisfy both total duration and postpartum coverage requirements.
  • Warfarin and heparins can be used during breastfeeding.

Aetiology

01

Previous thrombosis and thrombophilia

A personal VTE history or relevant thrombophilia can increase postpartum risk and change prophylaxis duration. Specialist plans should be visible to maternity and community teams.

02

Acquired postpartum triggers

Surgery, infection, immobility, obesity and significant bleeding can combine to increase risk. The accumulation of new factors after discharge can alter an initially appropriate plan.

Pathophysiology

  1. 1
    Hypercoagulability

    Pregnancy-associated changes in clotting persist after delivery. This state interacts with venous stasis and vascular injury to favour thrombus formation during postpartum recovery.

  2. 2
    Venous obstruction

    A thrombus impedes drainage from the affected limb or pelvic veins, producing swelling and discomfort. Proximal disease can cause symptoms extending beyond the calf.

  3. 3
    Pulmonary vascular obstruction

    Embolisation to pulmonary arteries impairs circulation through the lungs and can strain the right heart. Severe obstruction may cause hypoxaemia, shock or sudden collapse.

Clinical features and red flags

DVT presentation

Examine asymmetric swelling, tenderness and limb colour, noting proximal symptoms. A recent caesarean or immobility strengthens concern but is not necessary for the diagnosis.

Pulmonary embolism presentation

Ask about breathlessness onset, pleuritic pain, haemoptysis, presyncope and exercise tolerance. Normal oxygen saturation or a clear chest examination cannot alone exclude PE.

Bleeding and procedure history

Record postpartum bleeding, wound complications, epidural or spinal timing, catheter removal and anticoagulant doses. These details affect immediate treatment decisions and procedural safety.

Risk emerging after discharge

Infection, reduced mobility or an additional operation may change the prevention plan. Reassess when a woman returns to hospital even if her original discharge prescription was correct.

Red flags requiring action

  • Sudden unexplained shortness of breath or pleuritic chest pain.
  • Collapse, hypoxaemia or haemodynamic instability after delivery.
  • New unilateral painful leg swelling, especially involving the whole limb.
  • Neurological symptoms or unusual severe headache suggesting a different venous thrombosis site.

Investigations

  1. 01
    Compression duplex ultrasoundFirst step
    Why
    Confirm or exclude a suspected lower-limb venous clot.
    Interpretation and limitations
    Positive imaging supports therapeutic treatment. If the initial scan is negative but suspicion remains high, the RCOG DVT pathway uses repeat ultrasound on days three and seven.
  2. 02
    ECG chest radiograph and PE imaging
    Why
    Assess alternatives and arrange definitive pulmonary investigation.
    Interpretation and limitations
    A chest radiograph helps select further imaging and assess competing diagnoses. Persisting PE suspicion after an apparently negative study requires senior review and further testing when indicated.
  3. 03
    Blood count renal liver and coagulation tests
    Why
    Establish baseline safety information before anticoagulant treatment.
    Interpretation and limitations
    Kidney impairment affects LMWH and DOAC exposure; platelet abnormalities and active bleeding alter the risk assessment. Obtain tests promptly without creating avoidable delay in urgent treatment.
  4. 04
    Focused cardiac assessment in an unstable patient
    Why
    Support emergency decisions when severe embolism is suspected.
    Interpretation and limitations
    Bedside echocardiography may assist the resuscitation team when definitive imaging is unsafe. It does not replace standard diagnostic imaging in a stable patient.

Differential diagnosis

01

Cellulitis or local injury

Painful swelling may arise from skin infection or musculoskeletal injury. Clinical overlap means plausible alternatives do not eliminate the need for venous imaging when suspicion remains.

02

Pulmonary oedema

Pre-eclampsia and cardiac dysfunction can cause acute breathlessness after birth. Examination and targeted testing distinguish these conditions, which may also require emergency treatment.

03

Anaemia and deconditioning

Blood loss and reduced activity can impair exercise tolerance. Abrupt symptoms, pleuritic pain or unexplained deterioration should trigger assessment beyond these common recovery problems.

Management

01Suspected VTEInvestigate and cover thrombotic risk promptlyFirst stepNew symptoms suggest DVT or pulmonary embolism after birth.+
  1. 1Arrange urgent hospital evaluation, document vital signs and identify immediate bleeding or neuraxial contraindications.
  2. 2Start therapeutic LMWH while objective testing is arranged unless contraindicated, involving senior clinicians when competing risks complicate treatment.
  3. 3Use the appropriate DVT or PE imaging pathway and clearly document the plan if an initial result is negative or incomplete.
02Confirmed clotSet the full therapeutic treatment courseImaging confirms venous thrombosis or pulmonary embolism.+
  1. 1Confirm a therapeutic dose based on the chosen agent, appropriate weight and kidney function; distinguish it from any previous prophylactic dose.
  2. 2Plan at least three months total treatment and at least six weeks postpartum coverage, with a named team reviewing the final stop date.
  3. 3Discuss breastfeeding, oral options, injection technique and arrangements for monitoring before discharge.
03PreventionPrescribe prophylaxis after a revised risk assessmentThe woman has postpartum risk factors without a diagnosed acute clot.+
  1. 1Complete the maternity risk assessment after birth and repeat it when new illness or readmission changes risk.
  2. 2Select LMWH prophylaxis dose by the obstetric weight schedule and specify ten-day or six-week duration according to the assessed category.
  3. 3Teach self-administration and bleeding advice, confirm adequate supply and arrange reassessment if important risk factors persist.
04Competing risksCoordinate anticoagulation around bleeding or proceduresAnticoagulation is needed alongside active bleeding or recent neuraxial intervention.+
  1. 1Obtain senior obstetric, anaesthetic and haematology input with the exact timing of bleeding, procedures and previous doses.
  2. 2AlternativeUse mechanical measures or an alternative anticoagulation approach when indicated while a safe pharmacological plan is established.
  3. 3Document when medication can start or restart and who will reassess that decision if the clinical situation changes.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
Treats confirmed VTE and provides interim therapeutic cover for appropriate suspected cases.

Enoxaparin for therapeutic anticoagulation

A standard adult treatment schedule is 1 mg/kg subcutaneously every 12 hours; confirm the maternity weight-based regimen and adjust for renal impairment. Continue the agreed therapeutic course, including any planned oral transition.

Check active bleeding, platelet history, renal function and recent spinal or epidural procedures. Prophylactic 40 mg daily is not an equivalent treatment dose; severe renal impairment requires specialist dosing.

Prevents VTE when postnatal risk assessment indicates pharmacological prophylaxis.

Enoxaparin postpartum prophylaxis

RCOG's suggested prophylactic dose for a woman weighing 50–90 kg is 40 mg subcutaneously once daily; other weights need different doses. Prescribe 10 days or 6 weeks according to risk assessment.

Start only when bleeding and neuraxial safety allow. Confirm local timing rules after regional anaesthesia; reassess dose with renal impairment or extreme weight and extend duration if significant risks persist.

Offers a breastfeeding-compatible oral option for continuing treatment of postpartum VTE.

Warfarin after postpartum therapeutic LMWH

Start no earlier than postpartum day five, and later if haemorrhage risk remains high; use the anticoagulation service's loading nomogram and adjust oral daily doses to an INR target of 2–3.

Overlap with therapeutic heparin according to the initiation protocol until the INR is therapeutic for the required period. RCOG recommends daily INR testing during transfer from LMWH to warfarin. Review interacting medicines and discuss contraception because warfarin is generally unsuitable during pregnancy.

Complications

01

Life-threatening pulmonary embolism

Major embolism can produce haemodynamic collapse and require urgent reperfusion therapy. Resuscitation and multidisciplinary decision-making take priority over routine outpatient anticoagulation arrangements.

02

Post-thrombotic symptoms

Persistent venous damage may cause leg swelling, heaviness or discomfort after DVT. Ongoing symptoms need assessment and practical management during longer-term recovery.

03

Treatment-related bleeding

Anticoagulation can worsen uterine or wound bleeding. Recognising this risk supports careful monitoring and coordinated treatment rather than withholding all anticoagulation without an alternative plan.

Monitoring and follow-up

  • Check adherence and supply at early follow-up, asking about bruising, bleeding and injection difficulty in a way that encourages accurate reporting.
  • Repeat renal function or blood counts when clinical changes, the selected medicine or baseline abnormalities make monitoring necessary; routine anti-Xa testing is not required for every LMWH patient.
  • Reassess persistent dyspnoea, exercise limitation or leg symptoms after the acute event and refer for complications when recovery is not progressing as expected.
  • Before stopping anticoagulation, verify the actual treatment start date, total duration and continuing thrombotic risk with the responsible service.
  • For lactation decisions, review infant maturity, health, feeding and bleeding symptoms and obtain specialist advice when the infant falls outside routine SPS recommendations.

Special situations

Negative DVT imaging

RCOG's specific negative-ultrasound DVT pathway stops anticoagulation while arranging scans on days three and seven when suspicion is high. Persistent suspected PE follows a different rule: continue appropriate cover until it is definitively excluded.

Neuraxial timing matters

Anticoagulant timing around epidural insertion or removal depends on dose and renal function. Record exact administration times and seek anaesthetic advice rather than treating prophylactic and therapeutic intervals as interchangeable.

An oral option is individual

Current SPS lactation advice is more nuanced than a blanket DOAC prohibition. Warfarin remains preferred; selecting rivaroxaban or dabigatran requires assessment of the mother, infant and relevant product information.

Prevention after bleeding

Haemorrhage can temporarily prevent pharmacological prophylaxis while also contributing to later thrombosis risk. Reassess after haemostasis instead of leaving a temporary omission in place indefinitely.

Common pitfalls

  1. 01

    A prophylactic injection record should not be used to dismiss symptoms of a new pulmonary embolism.

  2. 02

    Stopping therapy at six weeks after birth can undertreat a clot diagnosed late in the puerperium.

  3. 03

    Applying negative DVT scan instructions to a patient with unresolved suspected PE can leave serious disease insufficiently covered.

  4. 04

    Choosing anticoagulation without discussing feeding, injections and monitoring access increases avoidable interruption of treatment.